» Articles » PMID: 25599874

Longitudinal Follow-up and Characterization of a Robust Rat Model for Parkinson's Disease Based on Overexpression of Alpha-synuclein with Adeno-associated Viral Vectors

Abstract

Testing of new therapeutic strategies for Parkinson's disease (PD) is currently hampered by the lack of relevant and reproducible animal models. Here, we developed a robust rat model for PD by injection of adeno-associated viral vectors (rAAV2/7) encoding α-synuclein into the substantia nigra, resulting in reproducible nigrostriatal pathology and behavioral deficits in a 4-week time period. Progressive dopaminergic dysfunction was corroborated by histopathologic and biochemical analysis, motor behavior testing and in vivo microdialysis. L-DOPA treatment was found to reverse the behavioral phenotype. Non-invasive positron emission tomography imaging and magnetic resonance spectroscopy allowed longitudinal monitoring of neurodegeneration. In addition, insoluble α-synuclein aggregates were formed in this model. This α-synuclein rat model shows improved face and predictive validity, and therefore offers the possibility to reliably test novel therapeutics. Furthermore, it will be of great value for further research into the molecular pathogenesis of PD and the importance of α-synuclein aggregation in the disease process.

Citing Articles

Quantitative MRI of a Cerebral Cryptococcoma Mouse Model for In Vivo Distinction between Different Cryptococcal Molecular Types.

Musetta L, Helsper S, Roosen L, Maes D, Croitor Sava A, Vanherp L J Fungi (Basel). 2024; 10(8).

PMID: 39194918 PMC: 11355240. DOI: 10.3390/jof10080593.


Residues 2 to 7 of α-synuclein regulate amyloid formation via lipid-dependent and lipid-independent pathways.

Dewison K, Rowlinson B, Machin J, Crossley J, Thacker D, Wilkinson M Proc Natl Acad Sci U S A. 2024; 121(34):e2315006121.

PMID: 39133842 PMC: 11348338. DOI: 10.1073/pnas.2315006121.


The AAV-α-Synuclein Model of Parkinson's Disease: An Update.

Bjorklund A, Mattsson B J Parkinsons Dis. 2024; 14(6):1077-1094.

PMID: 39031386 PMC: 11380285. DOI: 10.3233/JPD-240207.


Recalibrating the Why and Whom of Animal Models in Parkinson Disease: A Clinician's Perspective.

Sturchio A, Rocha E, Kauffman M, Marsili L, Mahajan A, Saraf A Brain Sci. 2024; 14(2).

PMID: 38391726 PMC: 10887152. DOI: 10.3390/brainsci14020151.


Characterisation of functional deficits induced by AAV overexpression of alpha-synuclein in rats.

Gubinelli F, Sarauskyte L, Venuti C, Kulacz I, Cazzolla G, Negrini M Curr Res Neurobiol. 2023; 4:100065.

PMID: 36632447 PMC: 9827042. DOI: 10.1016/j.crneur.2022.100065.